Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Tait D. Shanafelt,Xin V. Wang,Neil E. Kay,Curtis A. Hanson,Susan O'Brien,Jacqueline C. Barrientos,Diane F. Jelinek,Esteban Braggio,Jose F. Leis,Cong C. Zhang,Steven Coutre,Paul M. Barr,Amanda F. Cashen,Anthony R. Mato,Avina K. Singh,Michael P Mullane,Richard F. Little,Harry P. Erba,Richard Stone,Mark R. Litzow,Martin S. Tallman +20 more
Reads0
Chats0
TLDR
The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL.Abstract:
Background Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients wi...read more
Citations
More filters
Journal ArticleDOI
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
Jeff P. Sharman,Miklos Egyed,Wojciech Jurczak,Alan P Skarbnik,Alan P Skarbnik,John M. Pagel,Ian W. Flinn,Manali Kamdar,Talha Munir,Renata Walewska,Gillian Corbett,Laura Fogliatto,Yair Herishanu,Versha Banerji,Steven Coutre,George A Follows,Patricia F. Walker,Karin Karlsson,Paolo Ghia,Ann Janssens,Florence Cymbalista,Jennifer A. Woyach,Gilles Salles,William G. Wierda,Raquel Izumi,Veerendra Munugalavadla,Priti Patel,Min Hui Wang,Sofia Wong,John C. Byrd +29 more
TL;DR: The primary endpoint was progression-free survival between the two combination-therapy groups, assessed by independent review committee.
Journal ArticleDOI
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf,Can Zhang,Maneesh Tandon,Arijit Sinha,Anna-Maria Fink,Sandra Robrecht,Olga Samoylova,Anna M. Liberati,Javier Pinilla-Ibarz,Stephen Opat,Liliya Sivcheva,Katell Le Du,Laura M. Fogliatto,Carsten Utoft Niemann,Robert Weinkove,Sue Robinson,Thomas J. Kipps,Eugen Tausch,William Schary,Matthias Ritgen,Clemens M. Wendtner,Karl Anton Kreuzer,Barbara Eichhorst,Stephan Stilgenbauer,Michael Hallek,Kirsten Fischer +25 more
TL;DR: Patients with previously untreated chronic lymphocytic leukaemia given venetoclax plus obinutuzumab had a significantly longer progression-free survival than did patients given chlorambucilplus obinutsumab, and Median progression- free survival was not reached.
Journal ArticleDOI
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.
TL;DR: The significant milestones in the preclinical discovery and clinical development of BTK inhibitors are summarized to better understand the clinical and commercial potential as well as the directions being taken.
Journal ArticleDOI
Treatment of Chronic Lymphocytic Leukemia.
TL;DR: This research presents a novel approach called “ CAR-T cell reprograming,” which exploits the “ cellular “spiking” in the immune response to treat chronic lymphocytic leukemia with a single therapy.
Journal ArticleDOI
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Arnon P. Kater,Jenny Wu,Thomas J. Kipps,Barbara Eichhorst,Peter Hillmen,James D'Rozario,Sarit Assouline,Carolyn Owen,Tadeusz Robak,Javier de la Serna,Ulrich Jaeger,Guillaume Cartron,Marco Montillo,Julie Dubois,Eric Eldering,Clemens Mellink,Anne-Marie van der Kevie-Kersemaekers,Su Young Kim,Brenda Chyla,Elizabeth Punnoose,Christopher R. Bolen,Zoe June Assaf,Yanwen Jiang,Jue Wang,Marcus Lefebure,Michelle Boyer,Kathryn Humphrey,John F. Seymour +27 more
TL;DR: Efficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD, and Salvage therapy with ibrutinib after VenR achieved high response rates.
References
More filters
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillaume Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Kanti R. Rai,Thomas J. Kipps +10 more
TL;DR: The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
Journal ArticleDOI
A multiple testing procedure for clinical trials.
TL;DR: The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
TL;DR: Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.
Related Papers (5)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A. Woyach,Amy S. Ruppert,Nyla A. Heerema,Weiqiang Zhao,Allison M Booth,Wei Ding,Nancy L. Bartlett,Danielle M. Brander,Paul M. Barr,Kerry A. Rogers,Sameer A. Parikh,Steven Coutre,Arti Hurria,Jennifer R. Brown,Gerard Lozanski,James S. Blachly,Hatice Gulcin Ozer,Brittny Major-Elechi,Briant Fruth,Sreenivasa Nattam,Richard A. Larson,Harry P. Erba,Mark R. Litzow,Carolyn Owen,Charles S. Kuzma,Jeremy S. Abramson,Richard F. Little,Scott E. Smith,Richard Stone,Sumithra J. Mandrekar,John C. Byrd +30 more
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
Jan A. Burger,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Deepali Suri,Mei Cheng,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps +33 more
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillermo Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Nicholas Chiorazzi,Stephan Stilgenbauer,Kanti R. Rai,John C. Byrd,Barbara Eichhorst,Susan O'Brien,Tadeusz Robak,John F. Seymour,Thomas J. Kipps +17 more
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more